Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Emergent BioSolutions Inc. (EBS) Report Updated: Oct 21, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Emergent BioSolutions Inc. (EBS)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Emergent BioSolutions Inc.© quotemedia

Company Profile

Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in biodefense and commercial markets in the United States and internationally. The company’s Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; Vaccinia Immune Globulin Intravenous for addressing adverse events from smallpox vaccination; and RSDL (reactive skin decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing NuThrax, an anthrax vaccine product candidate based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; and PreviThrax, a recombinant protective antigen anthrax vaccine product candidate, as well as GC-072, the compound in the EV-035 series of broad spectrum antibiotics. Its Biosciences segment markets WinRho SDF, to treat autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; VARIZIG for post-exposure prophylaxis of chickenpox; and Episil to treat pain associated with oral mucositis. This segment is also developing IXINITY, a therapeutic to prevent bleeding episodes in people with hemophilia B; MOR209/ES414, treatment for metastatic castration resistant prostate cancer; Otlertuzumab, treatment for chronic lymphocytic leukemia. In addition, it provides contract manufacturing services to third-party customers. The company has an agreement with MorphoSys AG to develop and commercialize MOR209/ES414. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.